Trial assesses antibody therapy for chronic active antibody-mediated kidney transplant rejection
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 ...
Oct 26, 2024
0
31









